Kinfo
EyePoint Pharmaceuticals Inc. logo

EyePoint Pharmaceuticals Inc.

EYPTNASDAQHealthcare·US · USD
$14.30
+0.19 (+1.35%)
Close · 2026-06-30

Price

Key statistics

Valuation
Market cap1.20B USD
Enterprise value1.31B USD
Trailing P/E-4.51
Forward P/E-5.38
PEG ratio-0.09
Price / sales167.04
Price / book38.31
Profitability
Gross margin24.14%
Operating margin-450.65%
Profit margin93.41%
Return on assets-54.13%
Return on equity-102.71%
Income (TTM)
Revenue7.61M USD
Gross profit-224.75M USD
EBITDA-279.38M USD
Net income-271.60M USD
Diluted EPS-$3.51
Rev. growth (YoY)161.70%
Balance sheet
Total cash45.26M USD
Total debt17.62M USD
Debt / equity46.82
Current ratio6.66
Book value / share$0.40
Cash flow (TTM)
Operating cash flow-267.54M USD
Levered free cash flow-168.72M USD
Shares & price
Shares outstanding83.45M
Float70.48M
Held by institutions111.82%
Beta1.75
50-day MA$13.22
200-day MA$14.12
52-week high$19.11
52-week low$8.96
Dividends
Forward rate
$0.00
Yield
0.00%
Payout ratio
0.00%
Frequency
Unknown
Earnings (EPS)
DateEst.ActualSurprise2026-05-06-0.81-0.99−22.22%2026-04-150.500.53+6.00%2026-02-270.180.21+16.67%
About EyePoint Pharmaceuticals Inc.

EyePoint Pharmaceuticals Inc. is a specialty biopharmaceutical company focused on developing and commercializing innovative ophthalmic products. Its primary purpose is to treat serious eye disorders, particularly targeting diseases like wet age-related macular degeneration (AMD), diabetic macular edema, and retinal vein occlusion. EyePoint's unique approach leverages drug delivery technologies which offer sustained-release treatments, enhancing patient outcomes by providing consistent therapeutic levels over extended periods. The company operates within the biotechnology and healthcare sectors, impacting the pharmaceutical landscape by addressing unmet medical needs in ophthalmology. EyePoint Pharmaceuticals plays a significant role in the market through collaborations with leading eye care companies, advancing therapeutic research and expanding access to novel solutions for visual impairment. Based in Watertown, Massachusetts, the company continues to innovate and lead in the field of ocular drug development, contributing to the advancement of vision-related healthcare on a global scale.

Sector
Healthcare
Industry
Biotechnology
CEO
Dr. Jay S. Duker M.D.
Employees
165
Headquarters
Watertown, MA, United States

Frequently asked questions about EyePoint Pharmaceuticals Inc.